Belantamab mafodotin-blmf is a BCMA-directed antibody and microtubule inhibitor conjugate oncology therapy marketed as Blenrep. FDA approved it in October 2025 in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma after prior therapies. The product carries significant ocular toxicity risk and is dispensed through a REMS program.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
New CAR T-cell approaches targeting BCMA and CD19 simultaneously show encouraging early results, while researchers develop control strategies for CAR-T therapies including antibody-drug conjugates.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07227311 |
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) |
RECRUITING | PHASE2 |
| NCT07224672 |
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07217184 |
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT07217119 |
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT07150104 |
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT07150091 |
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT07084896 |
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT07019545 |
A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY |
NOT_YET_RECRUITING | PHASE2 |
| NCT06956170 |
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06868667 |
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma |
ACTIVE_NOT_RECRUITING | PHASE3 |
